Clinical trials recruiting in Lubbock, Texas

Phase breakdown

Conditions recruiting in Lubbock, Texas

Recruiting trials in Lubbock, Texas

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184944 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07185009 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
  NCT07499232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
  NCT06045754 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
  NCT06671483 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06588855 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819891 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
  NCT06419374 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  NCT07144280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• ACT for Individuals With MNCD and Their Care Partners
  NCT07239609 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07184996 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
  NCT07286058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
  NCT04852887 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female)
• EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
  NCT06401421 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female
• Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
  NCT06641089 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
  NCT06651281 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female)
• Heat and Exercise in Aging as Therapy (HEAT)
  NCT06580964 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years and older · Sex: All (male and female)
• Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
  NCT06903819 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD
  NCT07189442 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: Male
• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
  NCT07186101 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
  NCT03851445 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
  NCT03053193 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
  NCT07611214 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Pilot Testing a Novel Approach to Pediatric Obesity Treatment
  NCT06755827 · Phase: Phase 1, Phase 2 · Ages: 11 Years to 14 Years · Sex: All (male and female)
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female)
• Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
  NCT03934905 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 89 Years · Sex: All (male and female)
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
  NCT03418961 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Patients Being Treated With Anti-obesity Medication
  NCT06790160 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
  NCT06548542 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06029972 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
  NCT06619990 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
  NCT06772623 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  NCT05564377 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female)
• Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
  NCT07200830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Tirzepatide Impact Assessment Study
  NCT07740291 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Lubbock, Texas?

51 recruiting trials have at least one study site in Lubbock, Texas.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.